Valuing PYC's science, page-2

If they deliver on MYC it's likely significantly north of those figures.

The beauty with MYC is it's been untouchable to big pharma for over 40 years remaining as the grail. Breast cancer is really just a model of the bigger picture - with MYC relevant to such a vast array of different cancers if they can hit breast it's likely applicable across the rest. I assume at present they have only been able to display these breakthroughs in cells & often the case can be that once in the body they don't perform the same. I assume if they can put it in mice & it looks good displaying the same outcomes then pharma will be all over it, company will be fighting them off - question then I guess is will they wait for that data or will someone jump early to try and beat off competition albeit with a little more risk on unknown outcomes.

It's very positive that it's keeping things tiered with the new oncology focus but still keeping delivery of other companies drugs at the forefront which is significantly value adding in itself.